Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Mark-Up By Senate Finance Delayed Until After Recess

Executive Summary

The Senate Finance Committee will not mark up Medicare reform legislation that would establish a prescription drug benefit until after the August congressional recess.

You may also be interested in...



PBMs Would Compete For Medicare Enrollees Under Sen. Roth's Rx Drug Plan

Medicare would contract with multiple pharmaceutical benefit managers in each service area under Sen. Roth's (R-Del.) Medicare reform plan.

PBMs Would Compete For Medicare Enrollees Under Sen. Roth's Rx Drug Plan

Medicare would contract with multiple pharmaceutical benefit managers in each service area under Sen. Roth's (R-Del.) Medicare reform plan.

Roth Trades Stop-Loss For 80/20 Split: Appears Unattractive To Drug Industry

Finance Committee Chairman Roth's initial approach to catastrophic coverage in a Medicare drug benefit differs substantially from the other major proposals pending on Capitol Hill.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel